COPD patients who used asteogolimab medicine reported an increase in health-related quality of life compared to those on a placebo, showed the latest trials on the drug. The study conducted in partnership between Leicester’s Hospitals, the University of Leicester and Loughborough University, found that analysed 81 patients aged 40 and over, with moderate to severe COPD who had at least two exacerbations in the past year to find that the  rate of exacerbations (or attacks) over 48 weeks was reduced by 22% in those that received astegolimab versus placebo. The findings, published in the Lancet Respiratory Medicine, highlighted that COPD-ST2OP trial underscored the reduction of symptoms by targeting ST2 receptors in treating with asteogolimab.